Novo Nordisk (NYSE:NVO) stock is falling on Wednesday after the pharmaceutical company announced results for the second quarter of 2024.A major blow to the company comes from its revenue of $3.8 billion. That’s below the $4.1 billion in revenue that Wall Street was expecting. Even so, the company has plans to overcome this issue.Here’s what Novo Nordisk president and CEO Lars Fruergaard Jørgensen had to say on the matter.“We are pleased with the sales growth in the first half of 2024, which has enabled us t ...